MARKET

HNSPF

HNSPF

Hansoh Pharmaceu
OTCPK
4.610
NaN%
Closed 09:30 10/02 EDT
OPEN
--
PREV CLOSE
4.574
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.653
52 WEEK LOW
3.856
MARKET CAP
27.96B
P/E (TTM)
28.32
1D
5D
1M
3M
1Y
5Y
1D
GSK partner Hansoh posts late-stage trial win for bone cancer therapy
Seeking Alpha · 07/28 17:09
NextCure announces reverse merger with privately held Avere
Seeking Alpha · 07/14 11:10
GSK partner Hansoh posts late-stage trial win for lung cancer drug in China
Seeking Alpha · 07/10 11:29
About HNSPF
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.

Webull offers Hansoh Pharmaceutical Group Company Ltd stock information, including OTCPK: HNSPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HNSPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HNSPF stock methods without spending real money on the virtual paper trading platform.